İntravitreal ranibizumab enjeksiyonunun göz içi basıncına etkisi
Yükleniyor...
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Vasküler endotelyal büyüme faktör inhibitörü ranibizumabın göz içi basıncına etkisini incelemek.Gereç ve Yöntem: Eksüdatif yaşa bağlı maküla dejenerasyonu nedeniyle intravitreal ranibizumab enjeksiyon tedavisi alan 56 olgunun 61 gözü retrospektif olarak incelendi. Olguların enjeksiyondan sonra 1. gün, 1. ay, 3. ay ve 6. aydaki göz içi basınç değişimleri değerlendirildi. Bulgular: Olguların yaş ortalaması 72.6±7.5 idi. İntravitreal ranibizumab enjeksiyonu 61 göze uygulandı. Olguların takip süresi 6 aydı. Enjeksiyondan sonraki 1. günde olguların göz içi basınçları <21 mmHg, 1. ayda bir olguda >21 mmHg, 3. ayda bir olguda > 21 mmHg idi. Olguların enjeksiyon öncesi ile 1. gün, 1, 3 ve 6. ayda ölçülen ortalama göz içi basınç değerleri karşılaştırıldığında istatiksel olarak anlamlı bir değişiklik olmadığı tespit edildi (p>0.05). Sonuç: Eksudatif yaşa bağlı maküla dejenerasyonu nedeniyle intravitreal ranibizumab enjeksiyonu göz içi basıncına etkisi olmamakla birlikte bazı olgularda göz içi basınç artışına neden olmaktadır.
Purpose: To investigate the effect of ranibizumab a vascular endothelial growth factor inhibitor - on intraocular pressure.Material and Methods: Records of sixty-one eyes of 56 patients received intravitreal ranibizumab injection due to exudative age-related macular degeneration were investigated, retrospectively. Intraocular pressures measured 1 day, 1, 3 and 6 months after the injection were evaluated. There was no significant difference among intraocular pressure values measured before and after the injections.Results: The mean age of the patients was 72.6±7.5. Sixty one eye received intravitreal ranibizumab injection. The followup duration was 6 months. all the patients had intraocular pressure lower than 21 mmHg at first dat after the injection. At first month and third month, there was only one patient having intraocular pressure higher than 21 mmHg. . There was no significant difference among intraocular pressure values measured before and after the injections.Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.
Purpose: To investigate the effect of ranibizumab a vascular endothelial growth factor inhibitor - on intraocular pressure.Material and Methods: Records of sixty-one eyes of 56 patients received intravitreal ranibizumab injection due to exudative age-related macular degeneration were investigated, retrospectively. Intraocular pressures measured 1 day, 1, 3 and 6 months after the injection were evaluated. There was no significant difference among intraocular pressure values measured before and after the injections.Results: The mean age of the patients was 72.6±7.5. Sixty one eye received intravitreal ranibizumab injection. The followup duration was 6 months. all the patients had intraocular pressure lower than 21 mmHg at first dat after the injection. At first month and third month, there was only one patient having intraocular pressure higher than 21 mmHg. . There was no significant difference among intraocular pressure values measured before and after the injections.Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.
Açıklama
Anahtar Kelimeler
Göz Hastalıkları
Kaynak
Glokom Katarakt
WoS Q Değeri
Scopus Q Değeri
Cilt
9
Sayı
3
